Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Emergent Prep for IV Dye in Acute Stroke Patients With Allergy
- Conditions
- Dye AllergyStroke
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Global Neurosciences Institute
- Target Recruit Count
- 50
- Registration Number
- NCT05905900
Verapamil for Neuroprotection in Stroke
Phase 1
Recruiting
- Conditions
- Ischemic Stroke
- Interventions
- Drug: 10 mg Intra-arterial VerapamilDrug: 20 mg Intra-arterial Verapamil
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Global Neurosciences Institute
- Target Recruit Count
- 60
- Registration Number
- NCT03347786
- Locations
- 🇺🇸
AtlantiCare Regional Medical Center, Atlantic City, New Jersey, United States
🇺🇸St Mary Medical Center, Langhorne, Pennsylvania, United States
🇺🇸Crozer Chester Medical Center, Upland, Pennsylvania, United States
Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Global Neurosciences Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02285959
News
No news found